3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
14
Leukemia, Myeloid, Acute
11
Myelodysplastic Syndromes
9
Lymphoma
8
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
6
Leukemia
6
Hematologic Neoplasms
6
Neuroblastoma
4
Neoplasms
4
Lymphoma, Non-Hodgkin
4
Leukemia, Biphenotypic, Acute
4
Leukemia, B-Cell
4
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Melanoma
3
Leukemia, Lymphoid
3
Hodgkin Disease
3
Hematologic Diseases
3
Sarcoma
2
Rhabdoid Tumor
2
Recurrence
2
Preleukemia
2
Precancerous Conditions
2
Osteosarcoma
2
Neoplasms, Germ Cell and Embryonal
2
Neoplasms by Histologic Type
2
Multiple Myeloma
2
Lymphoproliferative Disorders
2
Lymphatic Diseases
2
Leukemia, Myelomonocytic, Juvenile
2
Leukemia, Myeloid
2
Interventions
Cyclophosphamide
16
Mycophenolic Acid
13
Tacrolimus
10
fludarabine
9
ruxolitinib
8
Busulfan
7
fludarabine phosphate
6
Whole-Body Irradiation
6
Sirolimus
6
Melphalan
6
Methotrexate
5
Thiotepa
4
ibrutinib
3
Specimen Handling
3
Cyclosporine
3
Abatacept
3
Stem Cell Transplantation
2
Radiotherapy
2
Hematopoietic Stem Cell Transplantation
2
Clofarabine
2
Biopsy
2
vedolizumab
1
tildrakizumab
1
itacitinib
1
blinatumomab
1
belumosudil
1
axatilimab
1
Vorinostat
1
Therapeutics
1
Rituximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Graft vs Host Disease
×
Mesna
×
1 year
×
Clear all
NCT04678401
2025-10-20
IS-free Treg HaploHCT
Dana-Farber Cancer Institute
Phase 1
Recruiting
30 enrolled